智通财经APP获悉，百心安-B(02185)再涨近10%，截至发稿，涨9.94%，报7.85港元，成交额1175.87万港元。
消息面上，蓝帆医疗此前表示，蓝帆柏盛凭借在出海领域的平台化能力与行业知名度，与百心安就其铂睿时Iberis™多极肾动脉射频消融(RDN)系统迅速达成“出海”合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。
华福证券发布研报称，经皮去肾交感神经术（RDN）是针对未控及顽固高血压器械新疗法。根据灼识咨询，预计 2032 年中国 RDN 年市场规模超过 100 亿元人民币。该行指出，百心安 Iberis RDN 系统是全球唯一获批上市能兼具经桡动脉（TRA）和经股动脉双入路 RDN，先发优势显著，国内已与远大健康、海外多国家地区联合蓝帆柏盛达成重磅战略合作；德国、法国已将 Iberis RDN 纳入医保，当前正为百心安商业化加速起点，建议关注百心安。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.